


Medical Neurogenetics, LLC Develops Anticonvulsant-Resistant Epilepsy Rapid Evaluation Testing

Metabolic and genetic results are returned as testing is completed within 7 days, allowing critical clinical decision making.

ATLANTA, GEORGIA, USA, August 2, 2014 /EINPresswire.com/ -- [Medical Neurogenetics, LLC](#) is a clinical laboratory that performs complex histology, biochemical testing, metabolic testing, protein chemistry testing, and genetic testing. Diagnostic testing for neurologic and cardiologic diseases are emphasized. With the Medical Neurogenetics, LLC proprietary [SmartDx](#) search engine, Next Generation Sequencing can be focused on cost effective patient diagnosis. By leveraging the combined strengths of the diagnostic platforms, Medical Neurogenetics, LLC recently launched Anticonvulsant-Resistant [Epilepsy Rapid Evaluation](#) Testing. Results are delivered to the clinician as they are completed, allowing rapid implementation into patient diagnostic and management strategies. Testing includes metabolic and genetic testing for clinically actionable diseases. All testing is completed in under seven days. With approximately 700 institutions world wide, Medical Neurogenetics, LLC is a leader in developing testing that is performed rapidly, is useful in clinical diagnosis and management, and provides the most cost effective testing options.

John M. Shoffner, MD
Medical Neurogenetics, LLC
678-357-9903
[email us here](#)



This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.